hyperCORE International Appoints New Executive Leadership to Accelerate Clinical Research Site Growth

GTTP

Jeffrey Smyth appointed as President to lead hyperCORE's strategic expansion.
The leadership refresh supports a dual-audience model for site networks and CROs.
CROs benefit from a streamlined, single-point-of-contact approach to site feasibility.
The network now connects over 50 sites and 120 investigators across 25+ therapeutic areas.

Impact - Why it Matters

This leadership transition signals a pivotal shift toward operational maturity for hyperCORE. By streamlining executive oversight, the platform enhances its ability to bridge the gap between independent research sites and CROs, ultimately reducing trial timelines and improving data quality through a unified, high-performing network of clinical experts.

Summary

hyperCORE International, a premier strategic scaling platform for clinical research, has officially announced the election of its new executive leadership team. Jeffrey Smyth assumes the role of President, supported by Seneca Harrison as Vice President, Claxton Copeland as Secretary, and Dustin Owen as Treasurer. This strategic transition reinforces the organization's dual-purpose mission to empower independent clinical research site networks while providing CROs with a streamlined, high-performing connection to diverse patient populations.

The newly appointed officers bring extensive expertise to guide hyperCORE’s evolution, ensuring sustainable growth and operational excellence. Under this leadership, the organization continues to facilitate rapid site feasibility, offering CROs 48 to 72-hour turnaround times across more than 50 locations. By fostering collaboration and shared resources, hyperCORE remains committed to scaling site networks without compromising the independence that defines their unique research capabilities.

As the network expands, this leadership shift positions hyperCORE to further its impact across more than 25 therapeutic areas. Through centralized strategic partnerships and deep operational experience, the new executive team is poised to enhance the efficiency of clinical trials, ensuring that sponsors and site networks can effectively navigate the complexities of modern medical research for the benefit of patients worldwide.

hyperCORE International Appoints New Executive Leadership to Accelerate Clinical Research Site Growth

GTTP

Jeffrey Smyth appointed as President to lead hyperCORE's strategic expansion.
The leadership refresh supports a dual-audience model for site networks and CROs.
CROs benefit from a streamlined, single-point-of-contact approach to site feasibility.
The network now connects over 50 sites and 120 investigators across 25+ therapeutic areas.